Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TENX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CFO (new) — Interim CFO Thomas McGauley resigned effective May 10, 2026, though he will continue consulting through month-end to support the transition.
Tenax Therapeutics appoints Thomas R. Staab as CFO with $428K salary, 450K stock options
Filed April 22, 2026 · Period ending April 22, 2026 · ~1 min read
Key Changes
-
high
Thomas R. Staab appointed CFO effective May 11, 2026, bringing 25+ years healthcare finance experience including prior CFO roles at LENSAR, BioCryst Pharmaceuticals, and Inspire Pharmaceuticals.
Item 5.02 verify on EDGAR → -
high
Staab's compensation package includes $428,000 base salary, 45% target bonus, 10,000 restricted stock units vesting over one year, and options for 450,000 shares vesting over four years with one-year cliff.
Item 5.02 verify on EDGAR → -
medium
Interim CFO Thomas McGauley resigned effective May 10, 2026, one day before Staab's start date. McGauley will continue consulting through at least end of May to support transition and complete Q1 10-Q filing.
Item 5.02 verify on EDGAR → -
low
Severance terms provide nine months base salary and benefits if terminated without cause, increasing to 12 months if termination occurs within one year of a corporate transaction.
Item 5.02 verify on EDGAR →
Summary
Tenax Therapeutics has hired Thomas R. Staab as its new Chief Financial Officer, effective May 11, 2026, replacing interim CFO Thomas McGauley who resigned the day prior. Staab brings substantial healthcare finance credentials, having most recently served as CFO of LENSAR, Inc. from 2020-2026, and previously holding CFO positions at BioCryst Pharmaceuticals and Inspire Pharmaceuticals over his 25+ year career.
The compensation package reflects a competitive offer for an experienced healthcare CFO: $428,000 base salary with 45% target bonus, plus significant equity incentives including 450,000 stock options and 10,000 restricted stock units. The options vest over four years with a one-year cliff, while RSUs vest over one year.
McGauley's orderly departure with continued consulting support through the Q1 10-Q filing suggests a planned transition rather than an emergency replacement. Investors should watch Staab's first earnings call and 10-Q filing for insights into his financial strategy and any changes to the company's capital allocation or operational priorities. The substantial option grant aligns his interests with long-term shareholder value creation.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 22, 2026, Tenax Therapeutics, Inc. (the “Company”) announced the appointment of Thomas R. Staab, II as Chief Financial Officer of the Company effective May 11, 2026 (the “Start Date”).
The company hired Thomas R. Staab as its new Chief Financial Officer starting May 11, 2026. Staab has over 25 years of healthcare finance experience, most recently serving as CFO of LENSAR, Inc. from May 2020 to May 2026, and previously held CFO roles at BioCryst Pharmaceuticals and Inspire Pharmaceuticals.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
In the event Mr. Staab’s employment is terminated by the Company without Cause, by Mr. Staab for Good Reason, or if the Company elects not to renew the Employment Agreement not in connection with a Corporate Transaction (as each term is defined in the Employment Agreement), Mr. Staab will be entitled to receive: (i) nine months of base salary, (ii) a pro-rated amount of the annual bonus that he would have received had 100% of goals been achieved for the fiscal year in which such termination occurs, and (iii) nine months of COBRA reimbursements or benefits payments, as applicable.
If terminated without cause or for good reason, Staab receives nine months of base salary, a prorated bonus at 100% target, and nine months of health benefits. If termination occurs within one year of a corporate transaction, these benefits increase to 12 months. The employment agreement automatically renews annually unless either party provides 90 days' notice.
Event · Item 8.01 — Other Events
Company appointed a new Chief Financial Officer and issued employment inducement stock options.
Added in current filing · verify on EDGAR →
On April 22, 2026, the Company issued a press release announcing the appointment of Mr. Staab as Chief Financial Officer and the issuance of employment inducement stock options to Mr. Staab.
The company appointed Mr. Staab as Chief Financial Officer on April 22, 2026. As part of his compensation package, Mr. Staab received employment inducement stock options. The full details are contained in a press release filed as an exhibit to this 8-K.
Event · Item 9.01 — Financial Statements and Exhibits
Tenax Therapeutics appointed Thomas R. Staab, II under an executive employment agreement with inducement equity awards.
Added in current filing · verify on EDGAR →
Executive Employment Agreement with Thomas R. Staab, II, dated April 9, 2026.
Tenax Therapeutics entered into an executive employment agreement with Thomas R. Staab, II on April 9, 2026. The 8-K discloses this as a material agreement but does not specify the executive's role or compensation terms in the body text. The agreement is filed as Exhibit 10.1.
Added in current filing · verify on EDGAR →
Form of Inducement Restricted Stock Unit Award Agreement.
The company issued inducement restricted stock unit awards, likely in connection with the new executive hire. Inducement awards are typically granted to attract new employees and are exempt from shareholder approval requirements under exchange rules. The form agreement is filed as Exhibit 10.2.
Added in current filing · verify on EDGAR →
Form of Inducement Stock Option Award Agreement (incorporated by reference to Exhibit 10.26 to the Company’s Form 10-K for the period ended December 31, 2024, filed with the SEC on March 25, 2025).
The company also references inducement stock option awards, using a form agreement previously filed. This suggests the new executive received both restricted stock units and stock options as part of the compensation package to join the company.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify